Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Aug…
Biotechnology
US, Bedford [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Stoke Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | -2.3100 | -2.661 | 0 | 11 | -84 | -117 | -83 | 2 | -88 | 2 | 31 | 25 |
| 2023 | -2.3900 | -2.383 | 12 | 9 | -93 | -104 | -102 | 1 | -107 | 1 | 38 | 20 |
| 2024 | -2.3800 | -2.033 | 8 | 17 | -104 | -90 | -112 | 3 | -114 | 3 | 41 | 37 |
| 2025 | - | -2.527 | - | 13 | - | -113 | - | 2 | - | 2 | - | 30 |
| 2026 | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |